We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phytosterols and Cardiovascular Risk Evaluated against the Background of Phytosterolemia Cases—A German Expert Panel Statement †.
- Authors
Windler, Eberhard; Beil, Frank-Ulrich; Berthold, Heiner K.; Gouni-Berthold, Ioanna; Kassner, Ursula; Klose, Gerald; Lorkowski, Stefan; März, Winfried; Parhofer, Klaus G.; Plat, Jogchum; Silbernagel, Günter; Steinhagen-Thiessen, Elisabeth; Weingärtner, Oliver; Zyriax, Birgit-Christiane; Lütjohann, Dieter
- Abstract
Phytosterols (PSs) have been proposed as dietary means to lower plasma LDL-C. However, concerns are raised that PSs may exert atherogenic effects, which would offset this benefit. Phytosterolemia was thought to mimic increased plasma PSs observed after the consumption of PS-enriched foods. This expert statement examines the possibility of specific atherogenicity of PSs based on sterol metabolism, experimental, animal, and human data. Observational studies show no evidence that plasma PS concentrations would be associated with an increased risk of atherosclerosis or cardiovascular (CV) events. Since variants of the ABCG5/8 transporter affect the absorption of cholesterol and non-cholesterol sterols, Mendelian randomization studies examining the effects of ABCG5/8 polymorphisms cannot support or refute the potential atherogenic effects of PSs due to pleiotropy. In homozygous patients with phytosterolemia, total PS concentrations are ~4000% higher than under physiological conditions. The prevalence of atherosclerosis in these individuals is variable and may mainly relate to concomitant elevated LDL-C. Consuming PS-enriched foods increases PS concentrations by ~35%. Hence, PSs, on a molar basis, would need to have 20–40 times higher atherogenicity than cholesterol to offset their cholesterol reduction benefit. Based on their LDL-C lowering and absence of adverse safety signals, PSs offer a dietary approach to cholesterol management. However, their clinical benefits have not been established in long-term CV endpoint studies.
- Subjects
ATHEROSCLEROSIS risk factors; CARDIOVASCULAR diseases risk factors; SCIENTIFIC observation; FOOD consumption; ANIMAL experimentation; GENETIC disorders; RISK assessment; DESCRIPTIVE statistics; PHYTOSTEROLS; LIPID metabolism disorders; DIETARY fats; DISEASE complications
- Publication
Nutrients, 2023, Vol 15, Issue 4, p828
- ISSN
2072-6643
- Publication type
Article
- DOI
10.3390/nu15040828